Market Research Analyst

Thursday, 25 May 2017

Global Angiosarcomas Treatment Market Key Trends & Industry Forecast 2016 - 2024

Rare and clinically highly variable, Sarcoma is a type of cancer that originates from mesenchymal cells transformation. Sarcoma defines as the major tumors, such as bone, breast, skin, fats and soft tissues. One such rare type of soft tissue tumor is called as Angiosarcomas. This tumor begins to grow in the cells of a blood vessels and can occur in any part of body. Angiosarcoma tumors involve rapidly proliferating cancerous cells originated from endothelial or mesenchymal sources and develop blood filled channels. Angiosarcoma harbors is the worst prognosis among all sarcoma subtypes.

Angiosarcomas treatment market classification

Depending on the instigation of tumor, Angiosarcomas are classified as hemagiosarcoma (begin in blood vessels) and lymphangiosarcome (tumor begins in lymph vessels). The major causes of the disease are unknown, however, lymphederma is considered as a key propeller of the disease condition. In addition to this, frequent and long term exposure of the radiation is also considered as an important cause.

The major symptoms include skin infections; however, the deeply situated tumors may not show any distinct symptom of the disease. The latter condition worsens the situation and may be a fatal one. The diagnostic procedures mainly include CT, MRI and PET scan. In addition, biopsy procedure has proved its effectiveness in the disease diagnosis. This disease has a very low incidence rate of 2-3 per million people and also occurs in patients of breast cancer who have undergone radiation therapy.

Obtain Report Details @
http://www.transparencymarketresearch.com/angiosarcomas-treatment-market.html

Angiosarcomas treatment market remedies

Angiosarcoma treatment requires medical attention from a multidisciplinary medical team and includes oncologists, surgeons and other medical team. The disease is treated primarily with surgical intervention. Chemotherapy is also used due to high risk of local relapse and distant metastatic disease. However, chemotherapy and radiation therapy are critical for treating Angiosarcomas before and after surgery. The most common chemotherapeutic drug for treating Angiosarcomas includes doxorubicin. However, combination therapy involving mesna, doxorubicin, and ifosfamide has also shown effectiveness against Angiosarcomas. There have been several attempts in last decade to develop drugs that target blood vessels growth stimulator VEGF and thereby cause shrinking of angiosarcomas. These drugs include bevacizumab, irinotecan, sildenafil, SU11248, BAY43-9006, and AMG706. Radiation therapy includes exposure of high power gamma and X-rays to irradiate the tumors.

Angiosarcomas treatment market research

In a recent research at University of North Carolina, researcher reported a monoclonal antibody targeted towards a protein known as SFRP2 found to inhibit growth of angiosarcoma. The study was initiated because SFRP2 acts as a potent stimulator of angiogenesis and it was therefore hypothesized that targeting SFRP2 could inhibit tumor growth. The study is still in very nascent stage and will enter into clinical trials provided the researchers obtain enough funding for their research. The major drivers of the market include steadily increasing prevalence of the disease. Although the disease is considered as rare (less than 1 percent of the sarcoma diagnosed population), the prevalence is increasing steadily. This is anticipated to drive the market during forecast period 2014 – 2020. In addition, extensive R&D practices also fuels the market growth. A number of drugs, such as, AMG-386, sildenafil, and many others are under pipeline studies and expected to enter in the market in coming 5-10 years. A major restraint in developing specific drug for treating Angiosarcomas is the limited number of people on which the drug can be tested to confirm its safety and efficacy. Angiosarcomas are so rare accounting for only 1% of sarcomas which in turn account for only 1 percent of all kinds of cancer.

The major players operating in the global Angiosarcomas market include Pfizer, Inc., Genentech, Inc., Bayer Healthcare, Janssen Products, LP, Sanofi S.A., and Amgen, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14942

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Demyelinating Diseases Therapeutics Market by Type & Application 2016 - 2024

Demyelinating diseases are those diseases which affect the nervous system mostly damaging the myelin sheath of neurones. Thus, causing distortion of signals in the affected nerves which further leads to the deficiency in sensation, cognition, movements or impairing of any other physical function carried out by the affected nerve. In addition, demyelinating diseases are classified into two types demyelinating leukodystrophic diseases and demyelinating myelinoclastic diseases. Demyelinating diseases may occur due to genetics irregularities, by infectious agents and by autoimmune reactions, though, at times, the cause may remain unknown. At times demyelination is caused by neuroleptics or extreme exposure to chemical agents.

The symptoms that are present in demyelinating diseases may differ from patient to patient. However, few of the common symptoms may include blurred double vision, ataxia, dysarthria, impaired muscle coordination, loss of sensation, hand paralysis and speech and hearing disorders.

Few of the guiding principles set for treating a person suffering from any of the demyelinating diseases include improving the patient's living environment and lifestyle, counselling, physical exercise and relaxation. A holistic treatment approach is considered more appropriate in such conditions.

Obtain Report Details @
http://www.transparencymarketresearch.com/demyelinating-diseases-therapeutics-market.html

The Demand for Demyelinating Diseases Therapeutics Market Expected to Gain Traction in the Coming Years

There are several demyelinating diseases caused due to the breakdown of nervous system. Higher prevalence of such incidences in the recent years is expected to favor the global demyelinating diseases therapeutics market. In other words, demyelinating diseases are often linked with disorders in the human nervous system, which is a part of neurology. Other factors expected to drive the global demyelinating diseases therapeutics market include changing lifestyle and diminishing quality of leaving the environment.

On the other hand, limited options of treatment available for treatment of demyelinating diseases remains the major concern for most players in the market. In addition, most contemporary demyelinating diseases drugs and therapies available in the market do not promise complete cure of such disorders. Moreover, the high-cost and low credibility of the latest drugs are other factors expected to negatively impact the overall market.

The ongoing research and development programs for improving the current durgs used for the treatment of demyelinating diseases are considered as a good news for the market. In addition, novel drugs in R&D pipeline is expected to favor the global demyelinating diseases in the near future. For instance, the recent introduction of monoclonal antibodies (MAbs) is a major factor considered to influence the market growth. These latest drugs are promising higher efficacy compare to current therapies.

Regional Segmentation

On the basis of region, the global demyelinating diseases therapeutics market has been segmented into six key regions namely North America, Western Europe, Eastern Europe, Asia Pacific (APAC), Latin America, and the Middle East & Africa (MEA). North America is considered as one of the major markets for demyelinating diseases therapeutics attributed to the rising number cases of demyelinating diseases in the region. In addition, the occurrence of demyelinating diseases in the U.S has grown significantly over the years leading to a higher demand for its treatment. Further, availability of advanced therapeutics and drugs is supplementing the growth of demyelinating diseases therapeutics market in the region. The European market is also expected to witness a healthy growth of the market owing to rising number of incidence, especially in countries such the U.K., Germany and Spain.

Key Players

Few of the key players identified in the global demyelinating diseases therapeutics market include Teva Pharmaceutical Industries Ltd., Baxalta, Geneuro Sa, and Pfizer Inc.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14795

About Us

Global Healthcare WLAN Market Analysis, Trends and Forecast by 2016 - 2024

Technology is making rapid inroads into the healthcare system. Storing the medical history on cloud and having real-time, location-independent access to it has become a key trend in the healthcare industry. Owing to the rapid advancements in the technological sector, many manual processes of the healthcare sector have been automated. Against the backdrop of these developments, the healthcare WLAN market is anticipated to witness steady growth during the forecast period 2016-2024. A combination of factors will contribute to the growth of the market during the forecast period. These range from growing healthcare budgets in emerging economies to rising awareness on the benefits of incorporating technology into healthcare.

Obtain Report Details @
http://www.transparencymarketresearch.com/healthcare-wlan-market.html

Healthcare WLAN Market: Key Drivers

From end-user perspective, hospitals, ambulatory surgical centers, and clinics are focusing on delivering high-quality, accurate services to their clients, owing to which adoption of technology is gaining traction. Although this trend is majorly observed in developed countries, steady economic growth in emerging countries is anticipated to provide an impetus to the growth of this market during the forecast period.

Emerging economies, for long, have faced an uphill task in providing quality healthcare services to their citizens. Burdened by high population and limited resources, healthcare services in developing countries have left a lot to be desired. However, consistent economic progress has created a burgeoning middle class that views health and well-being as a necessity rather than an afterthought. Also, access to new wealth has offered these countries an opportunity of revamping their existing healthcare structure. Adoption of technology to offer quality services on a real-time basis is gaining traction in these countries, and it is anticipated that during the forecast period, many emerging countries, especially in Asia Pacific, will witness robust adoption of WLAN technology in their healthcare systems.

Healthcare WLAN Market: Technological Innovation Boosting Adoption

Incorporation of WLAN in technology can also boost attendance rate for GP appointments. Billions of dollars are lost every year owing to non-attendance. Robust adoption of WLAN in healthcare is expected to reduce missed appointments, giving a fillip to the overall market.

In addition to demand from end-users, another key factor that is expected to ramp up adoption is technological innovation. 802.11ac Wave 2 wireless is enabling more healthcare providers to transmit information at a higher speed than previous technology models.

Challenges for Adoption of WLAN in Healthcare

While the global healthcare Wi-Fi market is anticipated to witness a steady growth in the future, there are certain challenges that need to be met before this technology becomes all-pervasive. Except for developed and fast-growing economies, awareness and adoption of WLAN in healthcare system is quite low in other regions of the world. Africa, home to over 1 billion people, is lagging in terms of adoption of technology and only South Africa has a robust system in place. Sluggish adoption in Africa can slow down the global rate; however, key players in the market have ample opportunities to tap into fast-growing economies in Asia Pacific.

Leading companies in the market are focusing on consolidating their position by launching innovative products in developed countries. The strategy for developing countries is based around pricing, and collaborating with regional players is a key component of the strategy.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14774

About Us

Global Chemoinformatics Market Key Trends & Industry Forecast 2016 - 2024

Transparency Market Research finds that recent advancements in drug discovery and development and the growing use of in-silico techniques are the leading factors driving the global chemoinformatics market. In a report titled “Chemoinformatics Market - Global Industry Analysis, Size, Share, Trends and Forecast 2016–2024”, TMR addresses the numerous queries readers may have regarding this emerging market and its prospects over the coming years.

The technique of chemoinformatics finds application in the collection, representation, and evaluation of chemical data, building statistical models, structure prediction, and database designing. It is also extensively used in information handling, molecular modeling, quantitative structure-activity relationship, food science, drug discovery and designing, screening, analytical chemistry, polymers, and material science.

The report studies the global chemoinformatics market on the basis of certain parameters and each of the segments are evaluated in absolute detail to furnish readers with a 360-degree outlook of the overall market. By way of application, the market can be divided into virtual screening, drug discovery, drug analysis and validation, and others. The major end users of chemoinformatics include public organizations, pharmaceutical companies, the chemical industry, and academic and research institutions.

Obtain Report Details @
http://www.transparencymarketresearch.com/chemoinformatics-market.html

From a geographical point of view, the chemoinformatics market is classified into Latin America, North America, Asia Pacific, Europe, and the Middle East and Africa. North America accounts for a major share in the global market, with Europe not too far behind. The chemoinformatics market in these two regions is driven by technological innovations and expansions, increased investments in research and development activities, high prevalence of lifestyle-associated diseases, and the presence of several leading companies. On the other hand, Asia Pacific holds immense potential for growth in the chemoinformatics market thanks to rising initiatives pertaining to drug research and development. Recognizing the lucrative nature of the APAC market in terms of low labor cost, lower cost of manufacturing, and comparatively lenient regulations, a number of multinational firms are setting up shop in Asia Pacific.

Some of the leading players competing in the global chemoinformatics market are Simulations Plus, Inc., Bio-Rad Laboratories, Inc., PerkinElmer Inc., KNIME.COM AG, OpenEye Scientific, Certara, L.P., Chemical Computing Group, Inc., Agilent Technologies, BIOVIA, Scilligence Cambridge Soft ACX, EPAM Systems, Accelrys Software Inc., The Cambridge Crystallographic Data Centre (CCDC), ChemAxon, Inc., Schrödinger, LLC, and Advanced Chemistry Development, Inc. (ACD/Labs). TMR notes that despite the nascent nature of the chemoinformatics market, there will be a number of well-established players entering this market in due course of time.

The report presents an in-depth evaluation of the most prominent companies in the chemoinformatics market and profiles some of the top names on the basis of key parameters such as company and business overview, financial performance, product portfolio, recent developments, and individual strengths and weaknesses. The study serves as an invaluable database of sharp and practical insights for clients looking to invest in the global chemoinformatics market.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14315

About Us

Global Coagulation Testing Market Key Trends & Industry Forecast 2016 - 2024

Coagulation tests are performed for diagnosis of the blood clotting system in our body. Different types of coagulation tests are carried out to identify the coagulation process. These tests can be done at hospitals, diagnostic labs, and private clinics and sometimes even at home care facilities. Coagulation tests are generally classified into two major types: global tests and Local or specific tests.Global tests are type of coagulation tests that are performed for diagnosis of the whole blood clotting process. They help in diagnosis of normal state of the blood coagulation and the pathological intensity of the coagulation system. Global tests are generally considered as the first line of diagnostics which provide a complete picture of disorders and malfunctions within the coagulation system. This is useful in identifying the level of problem and to identify the clotting disorder such as hyper or hypo coagulation. Few examples of the global tests are thromboelastography, thrombin generation test, thrombodynamics test.

Local tests are performed to identify the components of the blood coagulation system along with the separate coagulation factors. These are more specific than the global tests as there is a possibility of identification of the disorder location with the accuracy of coagulation factor. Few examples of the local tests are activated partial thromboplastin time and prothrombin time test.

Obtain Report Details @
http://www.transparencymarketresearch.com/coagulation-testing-market.html

Other examples of the coagulation tests include whole blood clotting time, full blood count and examination and platelet count test. Platelet count test is performed by two major techniques (light scattering, electronic aperture-impedance counting) to distinguish between platelets, leucocytes and erythrocytes. Likewise, other tests include platelet function, platelet aggregation, heparin induced platelet aggregation (diagnosis of heparin-associated thrombocytopenia), Hess test, activated partial thromboplastin time, factor activity assay, thrombin time test, reptilase time test, template bleeding time test, activated coagulation time. According to Universal Biosensors, Prothrombin test helps many of the physicians to administer a safe and effective dose of warfarin to the patients. This test helps determine if the patient is taking in high dose of warfarin which may put them at risk of serious bleeding and if the dose is too little they are at risk of thrombosis. Prothrombin time test allows physicians to adjust the diet and lifestyle changes of the patient according to the warfarin dosage.

The increased prevalence of numerous blood clotting disorders such as deep vein thrombosis, hemophilia, thrombophilia, along with growing geriatric population are driving the need for the coagulation testing. Added to the above, the technological advancements in coagulation testing devices such as the modern coagulometers are significantly drive the global demand for coagulation testing market. Hospitals are the largest service providers for the coagulation testing services. Lack of awareness, slow adoption of innovative testing methods especially in the developing countries, high cost of fully automated hemostasis equipment, and risk of side-effects associated with blood testing along with stringent regulations in the approval of coagulation testing devices and assay kits are the major restraints for the growth of coagulation testing devices and the services.

North America and Europe are the major regions for the coagulation testing due to rapid launch of anticoagulants and increased blood clotting disorders. However, Asia and the Latin America regions are identified as the highest scope for coagulation testing owing to increased prevalence of blood disorders, and rising investments by the government to improve healthcare infrastructure these regions. Countries such as China and India are expected to witness considerable growth during the forecast period, owing to growing geriatric population and increasing incidences of blood clotting disorders.

Some of the key players in the global coagulation testing market include Alere Inc., Hoffmann-La Roche AG, Sysmex Corporation, Abbott, Siemens AG, Axis-Shield Diagnostics Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14168

About Us

Global Virology and Bacteriology Testing Market Analysis by Segments, Size and Forecast 2016 - 2024

Virology and Bacteriology Testing Market: Overview

The study of viruses and bacteria is referred to as virology and bacteriology respectively and includes the identification, classification, and characterization of the various species. The demand for virology and bacteriology testing has increased of late with the growing incidence of various viral and bacterial infections.

The report offers an in-depth assessment on the overall virology and bacteriology testing market, highlighting the leading factors driving and hampering the market. The key opportunities in store and the challenges that lie ahead have also been identified and industry experts have offered their inputs on how to make the most of this information and gain ground in the virology and bacteriology testing market.

Obtain Report Details @
http://www.transparencymarketresearch.com/virology-bacteriology-testing-market.html

The global market for virology and bacteriology testing is studied on the basis of technology, end user, disease, and geography. Based on technology, the market comprises molecular diagnostics, information technology, immunoassays, diagnostic imaging, chromatography, monoclonal antibodies, artificial intelligence, gel microdroplets, differential light scattering, flow cytometry, and liposomes. The key end users of virology and bacteriology testing are clinics, hospitals, diagnostic centers, laboratories, and blood banks. By geography, the market report covers Europe, North America, Latin America, Asia Pacific, and the Middle East and Africa.

Virology and bacteriology testing can be done on a variety of diseases pertaining to the respiratory system, urinary tract, and bloodstream, gastrointestinal and periodontal diseases, sexually transmitted diseases caused by viruses and bacteria, and several other ailments such as connective tissue and joint diseases, central nervous system infections, cardiovascular ailments, and skin diseases.

Virology and Bacteriology Testing Market: Trends and Opportunities

The growth in the global market for virology and bacteriology testing is attributed mainly to the surge in respiratory infections and disorders. According to the World Health Organization, each year at least 3 million people all over the world die from chronic obstructive pulmonary disease (COPD) and at least 235 million people suffer from asthma. This significant patient population, in addition to a growing population of people suffering from tuberculosis, has greatly driven the demand for virology and bacteriology testing. Apart from this, the global market is fueled by rising healthcare expenditure across developed and developing economies, major technological advancements in the field of R&D, and increasing investments by public and private bodies. On the other hand, however, concerns pertaining to reimbursement policies and regulatory scenarios in several developing countries.

It has been observed that most companies have been relying on product development and commercialization in order to gain a larger share in the virology and bacteriology testing market. In addition to this, strategic collaborations also form a key component of many organizations’ growth strategy and recent geographical expansions have enabled these companies to strengthen their hold in the global virology and bacteriology testing market.

Virology and Bacteriology Testing Market: Regional Outlook

Among the key geographical segments covered in the report, North America and Europe are two of the most mature markets for virology and bacteriology testing. Growth in these regional markets has been strong over the years owing to the rapid adoption of advanced diagnostic and testing methods, higher spending on healthcare, presence of favorable government policies, and the presence of advanced clinical laboratories and medical device manufacturing companies. A rising geriatric population and the increasing incidence of various infectious diseases also contribute toward the growth of the virology and bacteriology testing market in North America and Europe.

Asia Pacific is a prominent market for virology and bacteriology testing, powered by emerging economies such as China, Japan, and India. These nations have been generating the maximum revenue owing to expanding R&D facilities in the field of diagnostics, increasing incidence of infectious diseases, and the development of innovative yet affordable testing equipment. Driven by these factors, Asia Pacific will continue to contribute significantly to the global virology and bacteriology testing market.

Companies Mentioned in the Report

Fujirebio Diagnostics Inc., Cepheid, Diasorin, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Scienion AG, Grifols, Qiagen, Eiken Chemical Co Ltd., Sequenom, bioMerieux SA, Siemens AG, Hologic Inc., Diamedix Inc., Leica Biosystems Nussloch GmbH, F. Hoffmann-La RocheLtd., and Abbot are some of the prominent players competing in the global virology and bacteriology testing market.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14063

About Us

Patient Registry Software Market - Global Industry Volume and Region Analysis - 2023

This report on the global patient registry software market provides an analysis for the period 2013 – 2023, wherein 2014 is the base year and the period from 2015 to 2023 is the forecast period. Data for 2013 has been included as historical information. The report covers all the prevalent trends and technologies playing a major role in the growth of the patient registry software market over the forecast period. It also highlights various drivers, restraints, and opportunities expected to influence the market growth during the said period. The study provides a holistic perspective on market growth, throughout the above forecast period in terms of revenue estimates (in US$ Mn), across different geographies, which include North America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA), and Latin America (LATAM).

Obtain Report Details @
http://www.transparencymarketresearch.com/patient-registry-software-market.html

Patient registries are the computerized databases that contain personal, medical, social, and financial data being reported by healthcare professionals and patients. For rare or chronic diseases, registries can provide vital epidemiological data such as incidence and prevalence, symptoms, and severity of the disease to researchers and healthcare professionals. Due to the continuous growth of chronic diseases, population and disease management is highly needed, which in turn drives the overall demand for patient registry software. The growing demand for patient registry software has led to the emergence of patient registry software vendors around the world, which has contributed to the growth of market size globally.

This research report provides in-depth analysis of the global patient registry software market on the basis of software types, disease areas, and end-users. The patient registry software types are public domain and commercial. The patient registry software on the basis of disease areas is divided into diabetes registry, cardiovascular registry, cancer registry, rare disease/orphan disease registry, and other chronic disease registry. The patient registry software end-user segment comprises government and commercial segments.

In terms of geographical regions, the report segments the global patient registry software market into North America, Europe, Asia Pacific, Middle East & Africa (MEA), and Latin America; the regions are analyzed in terms of revenue generation. The report provides cross-sectional analysis of the global patient registry software market in terms of market estimates and forecasts for all segments across different geographic regions.

The report also includes competitive profiling of major players engaged in developing patient registry software. Major business strategies adopted by them, their market positioning, and various recent developments have also been identified in the research report. This report also provides market share analysis of major players in the patient registry software market based on their 2014 revenues. Some of the major players profiled in the report include Global Vision Technologies, Inc., Quintiles Inc., Dacima Software Inc., PatientCrossroads, and Evado eClinical Solutions.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5498

About Us